Fount of Information

Acro Biosystems社 How to Pick the Suitable Target for Antibody-Drug Conjugates

How_to_Pick_the_Suitable_Target_for_Antibody-Drug_Conjugates_1.png
How to Pick the Suitable Target for Antibody-Drug Conjugates
ADCs (Antibody-drug conjugates) are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens with highly potent anti-cancer agents linked via a chemical linker, while sparing normal cells from damage, potentially minimizing the side effects associated with cancer therapy. Since the approval of the first ADCs in 2000, there are now nine different approved ADCs on the market and over 100 ADCs in the drug-development pipeline.

List of ADCs have been approved

How_to_Pick_the_Suitable_Target_for_Antibody-Drug_Conjugates_2.png

We believe that with the development hotspot of ADCs from hematomas to solid tumors, choosing the suitable drug target proteins will become more and more important.

 

ACROBiosystems has developed a series of products with different species and tags for a variety of hot targets, which are suitable for immune, antibody screening, SPR, cell activity detection and other experiments. ACROBiosystems is committed to
assisting you in drug development, and all SPR&BLI protocols are available for free. In addition, over expressed cell lines and kit products will be coming soon.

Hot Products

How_to_Pick_the_Suitable_Target_for_Antibody-Drug_Conjugates_3.png

ACROBiosystems is continuously developing more high-quality targeting proteins of ADCs. If you have any suggestions or customized requirements, please contact us.
Product Features
>>> High purity verified by MALS

How_to_Pick_the_Suitable_Target_for_Antibody-Drug_Conjugates_4.png

Fig1.The purity of Human Her2, His Tag (Cat. No. HE2-H5225) was more than 90% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.

How_to_Pick_the_Suitable_Target_for_Antibody-Drug_Conjugates_5.png

Fig 2.The purity of Human EGF R, His Tag(Cat. No. EGR-H5222) was more than 90% and the molecular weight of this protein is around 90-115 kDa verified by SEC-MALS.

>>> High affinity validated by SPR&BLI

  • SPR

How_to_Pick_the_Suitable_Target_for_Antibody-Drug_Conjugates_6.jpg

Fig 3.Herceptin (Trastuzumab)
captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Her2, His Tag (Cat. No.
HE2-H5225) with an affinity constant of 1.07 nM as determined in a SPR assay.

How_to_Pick_the_Suitable_Target_for_Antibody-Drug_Conjugates_7.jpg

Fig4.Erbitux (Cetuximab)
captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human EGF R, His Tag (Cat. No.
EGR-H5222) with an affinity constant of 1.3 nM as determined in a SPR assay.

  • BLI

How_to_Pick_the_Suitable_Target_for_Antibody-Drug_Conjugates_8.jpg

Fig 5.Loaded Herceptin (Trastuzumab) on AHC Biosensor, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 0.825 nM as determined in BLI assay.

How_to_Pick_the_Suitable_Target_for_Antibody-Drug_Conjugates_9.jpg

Fig 6.Loaded Erbitux (Cetuximab) on AHC Biosensor, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.23 nM as determined in BLI assay.

Based on the Biacore T200/8K platform and ForteBio Octet platform, ACROBiosystems provides SPR /BLI analytical services to our valued customers. The SPR/BLI analytical services include antibody screening, antibody pairing/group, kinetic analysis, and interaction measurement.

 

>>> Click to learn more about SPR /BLI analytical service

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。